Xilio Therapeutics Inc. Common Stock (XLO)

FairStock Score: 67/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for businesses that earn durable profits and sell below intrinsic value. Xilio does not fit that mold. It is a clinical-stage immuno-oncology company with 76 employees and no profitable year in the data. In fiscal Q2 2026, the quarter ended June 30, 2026, it reported revenue of $18.7 million and a net loss of $6.4 million, or diluted EPS of -$0.33. That was better than fiscal Q2 2025, the quarter ended June 30, 2025, when revenue was $8.1 million and net loss was $15.8 million. For FY2025, ended December 31, 2025, revenue was $43.8 million and net loss was $35.0 million, compared with FY2024 revenue of $6.3 million and net loss of $58.2 million. The top line is moving, but the company still consumes cash: trailing free cash flow was -$61.3 million, a -114.9% FCF yield against the $53.3 million market cap at the 2026-10-13 close. The moat, if any, is the pipeline—XTX501, Efarindodekin alfa, Vilastobart—and clinical data, not current financial strength. FairStock gives a Piotroski F-score of 3/9 and an Altman Z-score of -2.64, weak signals. Debt is low with D/E 0.09, but ROE is -55.03% and ROCE is -13.61%. At $9.22, P/B is 1.18 and P/E is -28.81; the price is not demanding on book value, but book value is being spent. FairStock assigns no Lynch category because of losses in each of the last four years. I would call this speculative, not a value investment.

In plain English: Xilio Therapeutics is a small experimental-stage cancer drug company. The business looks weak today because it has been losing money and using up cash, even though recent filed revenue has increased. At $9.22 on 2026-10-13, the price looks roughly modest against its accounting value, but not clearly cheap because the company has no profits and may need more money.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer